Jordyn Sava

Articles

Dr. Packiam discusses promise of pembrolizumab plus cabazitaxel/gemcitabine in urothelial carcinoma

July 26, 2022

Study results presented at the 2022 AUA Annual Meeting showed that pembrolizumab plus cabazitaxel and gemcitabine had promising early efficacy in heavily pretreated patients with high-risk non–muscle invasive urothelial carcinoma.